Department of Epidemiology, Lazio Region, Rome, Italy.
J Clin Pharm Ther. 2012 Feb;37(1):37-44. doi: 10.1111/j.1365-2710.2010.01242.x. Epub 2011 Feb 6.
Adherence to evidence-based drug therapy after acute myocardial infarction has increased over the last decades, but is still unsatisfactory. Our objectives are to set out to analyse patterns of evidence-based drug therapy after acute myocardial infarction (AMI), and evaluating socio-demographic differences.
A cohort of 3920 AMI patients discharged from hospital in Rome (2006-2007) was selected. Drugs claimed during the 12 months after discharge were retrieved. Drug utilization was defined as density of use (boxes claimed/individual follow-up; chronic use = 6+ boxes/365 days) and therapeutic coverage, calculated through Defined Daily Doses (chronic use: ≥80% of individual follow-up). Patterns of use of single drugs and their combination were described. The association between poly-therapy and gender, age and socio-economic position (small-area composite index based on census data) was analysed through logistic regression, accounting for potential confounders.
Most patients used single drugs: 90·5% platelet aggregation inhibitors (antiplatelets), 60·0%β-blockers, 78·1% agents acting on the renin-angiotensin system (ACEIs/ARBs), 77·8% HMG CoA reductase inhibitors (statins). Percentages of patients with ≥80% of therapeutic coverage were 81·9% for antiplatelets, 17·8% for β-blockers, 64·4% for ACEIs/ARBs and 76·1% for statins. The multivariate analysis showed gender and age differences in adherence to poly-therapy (females: OR = 0·84; 95% CI 0·72-0·99; 71-80 years age-group: OR = 0·82; 95% CI 0·68-0·99). No differences were observed with respect to socio-economic position.
The availability of information systems offers the opportunity to monitor the quality of care and identify weaknesses in public health-care systems. Our results identify specific factors contributing to non-adherence and hence define areas for more targeted health-care interventions. Our results suggest that efforts to improve adherence should focus on women and older patients.
在过去几十年中,急性心肌梗死(AMI)后遵循循证药物治疗的比例有所增加,但仍不令人满意。我们的目标是分析 AMI 后循证药物治疗的模式,并评估社会人口统计学差异。
从罗马出院的 3920 名 AMI 患者中选择了一个队列。检索出院后 12 个月内开具的药物。药物使用情况定义为使用密度(使用的药盒数/个体随访;慢性使用=6+药盒/365 天)和治疗覆盖率,通过定义的每日剂量(慢性使用:≥个体随访的 80%)计算。描述了单一药物及其组合的使用模式。通过逻辑回归分析多药治疗与性别、年龄和社会经济地位(基于人口普查数据的小区域综合指数)之间的关联,并考虑到潜在的混杂因素。
大多数患者使用单一药物:90.5%的血小板聚集抑制剂(抗血小板药物)、60.0%的β受体阻滞剂、78.1%的肾素-血管紧张素系统药物(ACEI/ARB)、77.8%的 HMG CoA 还原酶抑制剂(他汀类药物)。抗血小板药物、β受体阻滞剂、ACEI/ARB 和他汀类药物的治疗覆盖率≥80%的患者比例分别为 81.9%、17.8%、64.4%和 76.1%。多变量分析显示,性别和年龄与多药治疗的依从性存在差异(女性:OR=0.84;95%CI 0.72-0.99;71-80 岁年龄组:OR=0.82;95%CI 0.68-0.99)。在社会经济地位方面没有差异。
信息系统的可用性提供了监测护理质量和识别公共卫生保健系统薄弱环节的机会。我们的结果确定了导致不依从的特定因素,从而确定了更有针对性的医疗保健干预措施的领域。我们的结果表明,改善依从性的努力应侧重于女性和老年患者。